Biotech

Aldeyra Therapeutics announced today that Richard H. Douglas will join the company’s Board of Directors. Aldeyra is a biotech company that works on treatments for diseases related to aldehydes and Douglas is a former executive of Genzyme.

Aldeyra Therapeutics (NASDAQ: ALDX) announced today that Richard H. Douglas will join the company’s Board of Directors. Aldeyra is a biotech company that works on treatments for diseases related to aldehydes and Douglas is a former executive of Genzyme.
As quoted in the press release:

Dr. Douglas is the former Senior Vice President, Corporate Development, Genzyme Corporation. From 1989 to 2011, the year Genzyme was acquired by Sanofi (now Sanofi Genzyme), Dr. Douglas led Genzyme Corporation’s Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. Prior to his work at Genzyme Corporation, Dr. Douglas served in science and corporate development capacities at Integrated Genetics.

CEO Todd Brady says:

“As Aldeyra advances to late-stage clinical trials and initiates pre-commercial planning, Dr. Douglas will bring valuable perspective to our Board.”

Read the full press release here.

MARKETS

Markets
TSX19222.74-35.58
TSXV644.91-7.45
DOW30946.99-491.27
S&P 5003821.55-78.56
NASD11181.54-343.01
ASX6706.00+177.60

COMMODITIES

Commodities
Gold1819.88-3.56
Silver20.81-0.34
Copper3.760.00
Palladium1876.00+8.00
Platinum912.00+5.00
Oil112.02+2.45
Heating Oil4.10-0.02
Natural Gas6.51+0.01

DOWNLOAD FREE REPORTS

×